Clareo Health | Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)
Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Florida
With
Driver
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Adult patients (older than 18 years at time of treatment) with high risk prostate cancer who were treated with proton therapy at UFHPTI/Department of Radiation Oncology
Patients treated between 6/10/2010 through 4/26/17 with at least 2 years follow up
